KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$919000.0.

  • Castle Biosciences' Cash from Financing Activities fell 20966.59% to -$919000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.8 million, marking a year-over-year decrease of 19427.49%. This contributed to the annual value of $6.1 million for FY2024, which is 36714.53% up from last year.
  • Latest data reveals that Castle Biosciences reported Cash from Financing Activities of -$919000.0 as of Q3 2025, which was down 20966.59% from $101000.0 recorded in Q2 2025.
  • Castle Biosciences' Cash from Financing Activities' 5-year high stood at $10.6 million during Q1 2024, with a 5-year trough of -$5.4 million in Q4 2024.
  • For the 5-year period, Castle Biosciences' Cash from Financing Activities averaged around $442421.1, with its median value being $226000.0 (2023).
  • In the last 5 years, Castle Biosciences' Cash from Financing Activities plummeted by 69523.81% in 2022 and then skyrocketed by 176222.22% in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' Cash from Financing Activities stood at $126000.0 in 2021, then crashed by 695.24% to -$750000.0 in 2022, then plummeted by 339.6% to -$3.3 million in 2023, then crashed by 63.33% to -$5.4 million in 2024, then skyrocketed by 82.93% to -$919000.0 in 2025.
  • Its Cash from Financing Activities was -$919000.0 in Q3 2025, compared to $101000.0 in Q2 2025 and -$1.6 million in Q1 2025.